Levetiracetam Tablet, Film Coated
Product Images NDC 0615-8499

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 0615-8499). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Levetiracetam-tablets-structure (Levetiracetam Tabs 8498 8499 8500 8501 1)

Chemical structure diagram of levetiracetam, showing its molecular arrangement with labeled carbon, nitrogen, oxygen atoms, and functional groups.*

FDA Label Image

Principal Display Panel (Levetiracetam Tabs 8498 8499 8500 8501 10)

Label for Levetiracetam Tabs USP 750 mg oral tablet. The label includes multiple barcode stickers with lot number 8500, package quantity of 30 tablets, and storage instructions at 20°-25°C. It states the product is for institutional use only, manufactured by MSN for Novadoz, and packaged by Vangard Labs in Glasgow, KY. The label also includes a receipt date and time section and a note to dispense in a tight, light-resistant container.*

FDA Label Image

Principal Display Panel (Levetiracetam Tabs 8498 8499 8500 8501 11)

Label for Levetiracetam Tabs USP 1000 mg oral film-coated tablets by NCS HealthCare of KY, LLC dba Vangard Labs, packaged by Vanguard Labs in Glasgow, KY. The label shows a 30-count quantity, storage instructions at controlled room temperature (20-25°C), and multiple small barcode section panels for institutional use only.*

FDA Label Image

Levetiracetam-tablets-figure-1 (Levetiracetam Tabs 8498 8499 8500 8501 2)

A bar graph depicting the percentage of patients at three dose levels: Placebo (7.4%, N=95), Levetiracetam 1000 mg/day (37.1%, N=97), and Levetiracetam 3000 mg/day (39.6%, N=101). The y-axis represents the percentage of patients from 0% to 45%, with higher percentages for the Levetiracetam doses compared to placebo.*

FDA Label Image

Levetiracetam-tablets-figure-2 (Levetiracetam Tabs 8498 8499 8500 8501 3)

A bar chart showing the percentage of patients with a measured outcome across three groups: Placebo (111 patients) at 6.3%, Levetiracetam 1000 mg/day (106 patients) at 20.8%, and Levetiracetam 2000 mg/day (105 patients) at 35.2%. The y-axis represents the percentage of patients, ranging from 0% to 45%.*

FDA Label Image

Levetiracetam-tablets-figure-3 (Levetiracetam Tabs 8498 8499 8500 8501 4)

A vertical bar chart comparing the percentage of patients between placebo (N=104) and Levetiracetam 3000 mg/day (N=180). The placebo group shows 14.4% of patients, while the Levetiracetam group shows 39.4%. The y-axis represents the percentage of patients, ranging from 0% to 45%.*

FDA Label Image

Levetiracetam-tablets-figure-4 (Levetiracetam Tabs 8498 8499 8500 8501 5)

A bar graph comparing the percentage of patients for Placebo (19.6%) versus Levetiracetam (44.6%). The x-axis lists the groups: Placebo (N=97) and Levetiracetam (N=101), while the y-axis represents the percentage of patients from 0% to 45%. The Levetiracetam bar is notably higher than the Placebo bar.*

FDA Label Image

Levetiracetam-tablets-figure-5 (Levetiracetam Tabs 8498 8499 8500 8501 6)

A bar chart comparing the percentage of patients between two groups: Placebo (N=51) and Levetiracetam (N=58). The Placebo group shows 19.6% of patients, while the Levetiracetam group shows 43.1%, indicated by taller bars and a marked asterisk above the Levetiracetam bar. The y-axis represents the percentage of patients from 0% to 45%.*

FDA Label Image

Levetiracetam-tablets-figure-6 (Levetiracetam Tabs 8498 8499 8500 8501 7)

A bar chart comparing the percentage of patients between a Placebo group (N=84) and a Levetiracetam group (N=79). The Placebo bar shows 45.2% while the Levetiracetam bar shows 72.2%, with an asterisk above indicating statistical significance.*

FDA Label Image

Principal Display Panel (Levetiracetam Tabs 8498 8499 8500 8501 8)

Levetiracetam Tablets USP 250 mg film-coated oral tablets are shown in a package label from NCS HealthCare of KY, LLC dba Vangard Labs. The label includes multiple small barcode labels for individual tablets, box barcode, lot number 8498, and storage instructions at 20-25°C. The product is marked for institutional use with packaging by Vangard in Glasgow, KY.*

FDA Label Image

Principal Display Panel (Levetiracetam Tabs 8498 8499 8500 8501 9)

Levetiracetam Tabs USP 500 mg film-coated tablets label with lot number 8499 and quantity of 30 tablets. The label indicates packaging by Vangard Labs, Glasgow, KY, for Novadoz. Storage instructions include keeping at 20-25°C and dispensing in a tight, light-resistant container. The label also includes multiple smaller barcode labels for institutional use only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.